Key statistics
On Tuesday, Candel Therapeutics Inc (CADL:NMQ) closed at 6.15, 831.82% above the 52 week low of 0.66 set on Nov 03, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 6.48 |
---|---|
High | 6.54 |
Low | 6.06 |
Bid | 6.08 |
Offer | 6.51 |
Previous close | 6.43 |
Average volume | 190.19k |
---|---|
Shares outstanding | 32.08m |
Free float | 22.19m |
P/E (TTM) | -- |
Market cap | 206.31m USD |
EPS (TTM) | -1.70 USD |
Data delayed at least 15 minutes, as of Oct 08 2024 21:00 BST.
More ▼
Announcements
- Candel Therapeutics to Present Preclinical Data on Therapeutic Potential of CAN-3110 in Melanoma at SITC 2024 Annual Meeting
- Candel Therapeutics to Present at H.C. Wainwright 26th Annual Global Investment Conference
- Candel Therapeutics Reports Second Quarter 2024 Financial Results and Recent Corporate Highlights
- Candel Therapeutics to Participate in the H.C. Wainwright 2nd Annual Immune Cell Engager Virtual Conference
- Candel Therapeutics to Join Russell 3000® Index
- FDA Grants Orphan Drug Designation for CAN-3110 for the Treatment of Recurrent High-Grade Glioma
- Candel Therapeutics Reports Prolonged Overall Survival in Phase 2 Clinical Trial of CAN-2409 for Advanced Non-Small Cell Lung Cancer (NSCLC) in Patients Non-Responsive to Immune Checkpoint Inhibitor (ICI) Treatment at 2024 ASCO Annual Meeting
- Candel Therapeutics to Present at the Jefferies Global Healthcare Conference
- Candel Therapeutics to Host Non-Small Cell Lung Cancer (NSCLC) R&D Breakfast Panel During 2024 ASCO Annual Meeting
- Candel Therapeutics Reports First Quarter 2024 Financial Results and Recent Corporate Highlights
More ▼